Medtronic Raises 2027 Forecasts on Heart Device Sales Surge

Medtronic has significantly raised its fiscal 2027 revenue and profit forecasts, driven by escalating demand for its heart devices. The medical technology giant announced on Tuesday an increase in its revenue growth expectations, now anticipating an annual organic revenue rise of 7.25% to 7.75%, up from the previous 6.75% to 7.25% projection. The lower end of its adjusted per share profit forecast has also been revised upward to $5.94 from $5.90, with the upper limit remaining at $6.

Strategic Investments and Market Expansion

In a strategic move to bolster its cardiovascular offerings, Medtronic has committed $80 million to heart-valve repair device maker Pi-Cardia, with a potential acquisition option valued at $210 million. Additionally, the company has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States. According to Medtronic CEO Geoff Martha, these investments align with the company's focus on high-growth segments within the medtech industry.

Martha emphasized the growing impact of new growth platforms across Medtronic's business segments during a post-earnings call. He noted the company's steady merger and acquisition activity, aimed at prioritizing segments with large patient pools and substantial growth potential.

Strong Performance in Cardiovascular Segment

Medtronic's cardiovascular segment reported a robust 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by the company's pulsed field ablation portfolio, which experienced an impressive 88% surge. The portfolio is utilized in complex cardiovascular procedures, particularly for treating irregular heart rhythms.

The company's financial performance exceeded expectations, with an adjusted quarterly per share profit of $1.45 on revenue of $9.76 billion, surpassing analysts' estimates of $1.39 on $9.55 billion, according to LSEG-compiled data. Medtronic's finance chief, Thierry Pieton, mentioned that the company benefited from tariff refunds that nearly offset the duties incurred during the quarter. However, future refunds have not been factored into the company's outlook.

As Medtronic continues to capitalize on the rising demand for advanced cardiovascular solutions, its strategic investments and strong financial performance position the company for sustained growth in the coming years.